Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Adalimumab Induces a Wound Healing Profile in Patients with Hidradenitis Suppurativa by Regulating Macrophage Differentiation and Matrix Metalloproteinase Expression

ABSTRACT: Adalimumab (ADA) is the only FDA-approved treatment for moderate-to-severe hidradenitis suppurativa (HS), whereas etanercept (ETN) and certolizumab-pegol (CZP) have been shown to be ineffective, suggesting that the mechanism of action of ADA is distinct in HS and may contribute to improved wound healing. Given that macrophages (Mφ) play pivotal roles throughout the wound healing process, an in-vitro Mφ differentiation assay was carried out to assess the impact of TNF-anti-TNF complexes on these cells. TNF-ADA complexes exhibited stronger inhibitory effects on inflammatory Mφ differentiation. Moreover, RNA sequencing revealed several unique wound healing profiles for TNF-ADA-treated inflammatory Mφs, which were not observed for those treated with either TNF-ETN or TNF-CZP, including the inhibition of the matrix metallopeptidase (MMP) pathway. In addition, ADA administration was found to significantly reduce the levels of inflammatory MMPs -1 and -9 while promoting wound healing MMP-13 and tissue inhibitor of metalloproteinases 2 (TIMP-2) levels in the circulation of those HS patients who responded to treatment. Our in-vitro findings demonstrate that TNF-ADA-treated inflammatory Mφs exhibit a distinct profile resembling wound healing. Moreover, ADA not only differentially regulates MMP expression in HS patients responding to the therapy but potentially induces a transition to a profile suggestive of wound healing.

ORGANISM(S): Homo sapiens

PROVIDER: GSE166920 | GEO | 2021/04/14

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Therapeutic TNF Inhibitors Exhibit Differential Levels of Efficacy in Accelerating Cutaneous Wound Healing

Project description:Adalimumab, but neither etanercept nor certolizumab-pegol, has been reported to induce a wound healing profile in the circulation of patients with hidradenitis suppurativa (HS), a chronic inflammatory skin disease. However, the role of tumor necrosis factor alpha (TNF) inhibitors in cutaneous wound healing in vivo is still unclear. To examine and compare the efficacy of various TNF inhibitors in cutaneous wound healing in vivo, a human TNF knock-in Leprdb/db mouse model was established to model the impaired cutaneous wound healing as seen in HS. The vehicle group exhibited severe impairments in cutaneous wound healing. In contrast, adalimumab significantly accelerated healing, confirmed by both histologic assessment and a unique healing transcriptional profile. Moreover, adalimumab and infliximab showed similar levels of efficacy, but golimumab was less effective, along with etanercept and certolizumab-pegol. In line with histologic assessments, proteomics analyses from healing wounds exposed to various TNF inhibitors revealed distinct and differential wound healing signatures that may underlie the differential efficacy of these inhibitors in accelerating cutaneous wound healing. Taken together, these data revealed that TNF inhibitors exhibited differential levels of efficacy in accelerating cutaneous wound healing in the impaired wound healing model in vivo likely through distinct mechanisms of action related to the structure of the biologic or its ability to bind TNF.

2023-09-11 | GSE242837 | GEO

Therapeutic TNF Inhibitors Exhibit Differential Levels of Efficacy in Accelerating Cutaneous Wound Healing

Project description:Adalimumab is the only FDA- and EMA-approved treatment for moderate-to-severe hidradenitis suppurativa (HS), suggesting that the mechanism of action of adalimumab is distinct in HS and may contribute to improved wound healing. We have demonstrated that adalimumab, but neither etanercept nor certolizumab-pegol, induces a wound healing profile in vitro, which may underlie the differences in efficacy between various anti-TNF agents. To examine and compare the efficacy of therapeutic TNF inhibitors in chronic cutaneous wound healing in vivo, a human TNF knock-in Leprdb/db mouse model was established. The vehicle group exhibited severe impairments in cutaneous wound healing. In contrast, adalimumab significantly accelerated healing, confirmed by both histologic assessment and a unique healing transcriptional profile. Moreover, adalimumab and infliximab showed similar levels of efficacy, but golimumab was less effective, along with etanercept and certolizumab-pegol. In line with histologic assessments, proteomics analyses from healing wounds exposed to various TNF inhibitors revealed distinct and differential wound healing signatures that may underlie the differential efficacy of therapeutic inhibitors in accelerating chronic wound healing.

2023-09-11 | PXD040275 | Pride

Multi-omics and Machine Learning Accurately Predicts Clinical Response to Adalimumab and Etanercept Therapy in Patients with Rheumatoid Arthritis [RNA-Seq]

Project description:Objectives: To predict response prior to anti-TNF treatment and comprehensively understand the mechanism how patients respond differently to anti-TNF treatment in rheumatoid arthritis (RA). Methods: Gene expression and/or DNA methylation profiling on PBMC, monocytes, and CD4+ T cells, from 80 RA patients before initiating either adalimumab (ADA) or etanercept (ETN) therapy was studied. After 6-month treatment response was evaluated according to the EULAR criteria of disease response. Differential expression and methylation analyses were performed to identify the response-associated transcriptional and epigenetic signatures. Machine learning models were built using these signatures by random forest algorithm to predict response prior to anti-TNF treatment and were further validated by a follow-up study. Results: Transcriptional signatures in ADA and ETN responders are divergent in PBMCs, and this phenomenon was reproduced in monocytes and CD4+ T cells. The genes upregulated in CD4+ T cells of ADA responders were enriched in the TNF signaling pathway, while very few pathways were differential in monocytes. Differential methylation positions (DMPs) of responders to ETN but not to ADA are majorly hypermethylated. The machine learning models to predict the response to ADA and ETN using differential genes reached overall accuracy of 85.9% and 79%, respectively. The models using DMPs reached overall accuracy of 84.7% and 88% for ADA and ETN, respectively. A follow-up study validated the high performance of these models. Conclusions: Machine learning models based on these molecular signatures could accurately predict response before ADA and ETN treatment, paving the path towards personalized anti-TNF treatment.

2020-08-24 | GSE138746 | GEO

Multi-omics and Machine Learning Accurately Predicts Clinical Response to Adalimumab and Etanercept Therapy in Patients with Rheumatoid Arthritis [Methylation array]

2020-08-24 | GSE138653 | GEO

Gene Expression Profiles Associated with Mφ Spatial Aggregation for HCC

Project description:To validate that the aggregation pattern identifies a pro-tumoral Mφ subset in HCC, we have employed microarray expression profiling as a discovery platform to identify the molecular and functional implications of Mφ spatial distribution in HCC. Gene ontology (GO) and gene-set enrichment analyses (GSEA) revealed that tissues rich in aggregated Mφs significantly upregulated tissue remodeling pathways and “M2” Mφ-associated genes, while pro-inflammatory “M1” gene sets were more pronounced in HCCs with predominantly scattered Mφs. These results indicate that Mφ aggregation signifies a transition to a multifaceted, pro-tumoral phenotype, highlighting the intricate relationship between spatial distribution and function of Mφs in the tumor milieu.

2024-09-08 | GSE276428 | GEO

Enteric glial cells favor accumulation of anti-inflammatory macrophages during the resolution of muscularis inflammation

Project description:Monocyte-derived macrophages (Mφs) are crucial regulators during muscularis inflammation. However, it is unclear which micro-environmental factors are responsible for monocyte recruitment and anti-inflammatory Mφ differentiation in this paradigm. Here, we investigate Mφ heterogeneity at different stages of muscularis inflammation and determine how environmental cues can attract and activate tissue-protective Mφs. Results showed that muscularis inflammation induced marked alterations in mononuclear phagocyte populations associated with a rapid infiltration of Ly6c+ monocytes that locally acquired unique transcriptional states. Trajectory inference analysis revealed two main pro-resolving Mφ subpopulations during the resolution of muscularis inflammation, i.e. Cd206+ MhcIIhi and Timp2+ MhcIIlo Mφs. Interestingly, we found that damage to the micro-environment upon muscularis inflammation resulted in EGC activation, which in turn stimulated monocyte infiltration and the consequent differentiation in anti-inflammatory CD206+ Mφs via CCL2 and CSF1, respectively. In addition, CSF1-CSF1R signaling was shown to be essential for the differentiation of monocytes into CD206+ Mφs and EGC proliferation during muscularis inflammation. Our study provides a comprehensive insight into pro-resolving Mφ differentiation and their regulators during muscularis inflammation. We deepened our understanding in the interaction between EGCs and Mφs, thereby highlighting pro-resolving Mφ differentiation as a potential novel therapeutic strategy for the treatment of intestinal inflammation.

2022-09-12 | GSE167465 | GEO

Enteric glial cells favor accumulation of anti-inflammatory macrophages during the resolution of muscularis inflammation

2022-09-12 | GSE167464 | GEO

Enteric glial cells favor accumulation of anti-inflammatory macrophages during the resolution of muscularis inflammation

2022-09-12 | GSE167463 | GEO

Enteric glial cells favor accumulation of anti-inflammatory macrophages during the resolution of muscularis inflammation

2022-09-12 | GSE167461 | GEO

Enteric glial cells favor accumulation of anti-inflammatory macrophages during the resolution of muscularis inflammation

2022-09-12 | GSE167460 | GEO